Bombay HC Quashes Prosecution for Sub-Standard Drug Manufacturing Due to Delayed Sample Analysis

Introduction

In a significant ruling emphasizing the importance of strict adherence to statutory timelines in drug quality testing, the Bombay High Court (Nagpur Bench) has quashed a criminal prosecution against the directors and company behind the manufacture of an allegedly sub-standard drug. Justice M.M. Nerlikar, in his judgment dated January 17, 2026, in Ashwani & Ors. v. State of Maharashtra (Criminal Writ Petition No. 967 of 2024), held that the failure to analyze drug samples within the mandatory 60-day period under Rule 45 of the Drugs and Cosmetics Rules, 1945, vitiates the entire proceedings. This decision not only provides relief to the petitioners—directors of M/s Oscar Remedies Pvt. Ltd.—but also issues comprehensive directions to the Maharashtra Food and Drugs Administration to prevent future lapses that could endanger public health. The court's observations highlight systemic delays in the Drugs Department, which, if unchecked, allow sub-standard drugs to circulate, undermining the protective objectives of the Drugs and Cosmetics Act, 1940.

Case Background

The petitioners in this case include Mr. Ashwani Lamba, Mr. Navdeep Kumar, Smt. Asha Dhingra, Mr. Ashwani Kumar, and M/s Oscar Remedies Pvt. Ltd., a pharmaceutical company based in Yamunanagar, Haryana. They were facing prosecution under the Drugs and Cosmetics Act, 1940, for allegedly manufacturing a sub-standard drug, specifically RTZOL-DSR capsules (containing Rabeprazole Sodium and Domperidone), batch C-2111250, manufactured in November 2021 with an expiry date of October 2023.

The dispute arose from actions taken by the respondent, the State of Maharashtra, through Drug Inspector Nalanda B. Urkude of the Food and Drugs Administration in Gadchiroli. On July 12, 2022, the Drug Inspector visited City Medical Shop in Gadchiroli and drew samples of the drug. These samples were forwarded to the Government Analyst on July 14, 2022, for testing as required under Chapter IV of the Act. However, the analysis process was marred by significant delays: the Government Analyst sought an extension only on November 1, 2022—well beyond the 60-day deadline from receipt—and the report, declaring the drug "not of standard quality," was issued as late as January 18, 2023.

Despite the delay, the authorities proceeded with prosecution by launching a complaint on August 23, 2023, before the Chief Judicial Magistrate, Gadchiroli, in S.C.C. No. 637/2023 ( State of Maharashtra v. Ashwani Lamba and Ors. ). A notice informing the manufacturer of the report was served only on April 19, 2023, nearly four months after the report's receipt. The petitioners filed the writ petition seeking to quash the proceedings, arguing that the delays violated their statutory rights and rendered the prosecution unsustainable.

The core legal questions before the court were: (1) Whether the non-compliance with the 60-day analysis timeline under Rule 45 of the 1945 Rules, including the belated request for extension, vitiates the criminal proceedings; and (2) The broader implications of departmental lapses on public health enforcement under the 1940 Act. The timeline underscores the procedural irregularities: samples drawn and sent in July 2022, extension sought post-deadline in November 2022, report in January 2023, notice in April 2023, and complaint in August 2023—all while the drug's shelf life was still active.

Arguments Presented

The petitioners, represented by advocate Shri V.R. Borkar, contended that the prosecution was fundamentally flawed due to the Drugs Department's failure to comply with Rule 45 of the Drugs and Cosmetics Rules, 1945. Rule 45 mandates that the Government Analyst must furnish a test report within 60 days of receiving the sample, with any extension sought only if necessary, by providing specific reasons to the government within that period. In this case, the 60-day window from July 14, 2022, expired around September 12, 2022, but the extension was requested on November 1, 2022—almost two months late. The petitioners argued that this delay not only violated the rule but also deprived them of their right under Sections 25(3) and 25(4) of the 1940 Act to have the sample re-analyzed by the Central Drugs Laboratory, as the sample's integrity could degrade over time, affecting the accuracy of any re-test.

Relying heavily on the precedent in Swapnil s/o Liladhar Mane & Ors. v. State of Maharashtra (2024(4) Mh.L.J. (Cri.) 673), a decision from the same court, the petitioners emphasized that timely analysis is essential to maintain the drug's quality for accurate testing. They asserted that such procedural lapses render the entire complaint vitiated, benefiting manufacturers of sub-standard drugs at the expense of public safety. Factually, they highlighted the absence of any reminder from the Drug Inspector to the Analyst and the unexplained four-month delay in serving the notice post-report.

On the other hand, the State, represented by Assistant Public Prosecutor Shri A.R. Chutke, opposed the petition, arguing that the petitioners themselves failed to exercise their statutory right to send samples for re-analysis after receiving the notice on April 19, 2023. The State pointed out that the complaint was filed on August 23, 2023, before the drug's expiry in October 2023, ensuring the proceedings were within the valid shelf life. They contended that mere technical non-compliance with Rule 45 does not automatically warrant quashing, especially when sub-standard drugs pose a grave public health risk. The extension, though belated, was sought, and the report ultimately confirmed non-standard quality. The State urged the court to view the matter holistically, prioritizing the Act's objective of protecting consumers from harmful drugs rather than allowing procedural delays to shield manufacturers. They also noted that the Drug Inspector's actions were in good faith, and the petitioners' inaction on re-testing undermined their grievance.

Legal Analysis

Justice Nerlikar meticulously examined Rule 45, which outlines the duties of Government Analysts: to analyze samples sent under Chapter IV of the Act and provide reports within 60 days, with a proviso allowing extensions only if sought timely with specific reasons. The court reiterated that this timeline is not discretionary but mandatory, as delays compromise the sample's quality, ensuring accurate results crucial for prosecutions. The judge distinguished between mere procedural irregularities and substantive violations, holding that the belated extension request—post-60 days without prior grant or reasons—fatally undermined the proceedings.

The ruling drew directly from Swapnil s/o Liladhar Mane & Ors. v. State of Maharashtra , where the court quashed a similar prosecution due to a one-year delay in analysis, observing: "The analysis of the sample within a period of sixty days is necessary to ensure the standard of quality for the purpose of the analysis and an accurate report... The delayed analysis of the sample in such a case violates the vital right of the accused to get the sample rechecked." This precedent was pivotal, as it established that non-compliance with Rule 45 vitiates prosecutions, supported by a catena of judgments emphasizing time as the essence in drug testing to prevent degradation.

The court also invoked the four-fold objectives of the Drugs and Cosmetics Act, 1940: ensuring drug safety, efficacy, and quality; preventing sub-standard products from reaching consumers; establishing legal standards for manufacture and distribution; and protecting public health from harmful substances. Justice Nerlikar critiqued the Department's "leniency," noting how delays—such as the four-month gap between report receipt and notice service—frustrate these goals, inadvertently benefiting errant manufacturers. He clarified that while manufacturers must be dealt with sternly for sub-standard drugs, enforcement officers cannot be indifferent to procedural safeguards, as lapses allow unsafe drugs to persist in circulation.

Additionally, the judgment referenced directions from the High Court of Karnataka in Criminal Petition No. 8341 of 2018 (dated August 30, 2024), which mandated systemic improvements like online tracking for drug testing. This informed the Bombay HC's broader analysis, underscoring the need for accountability in regulatory bodies. The decision makes clear distinctions: quashing here stems not from the drug's quality but from procedural infirmities that prejudice fair trial rights, differing from cases where delays are minor or excused with reasons.

Key Observations

The judgment is replete with strong rebukes against departmental inefficiencies, extracting pivotal excerpts that underscore the court's frustration and policy directives:

1. On the necessity of timelines: "The analysis of the sample within a period of sixty days is necessary to ensure the standard of quality for the purpose of the analysis and an accurate report. On this count also, the prosecution against the accused... cannot be sustained." (Quoting and applying Swapnil precedent.)

2. Highlighting systemic issues: "...there are 'n' number of cases wherein the lapses on the part of the department of the Drugs and their officers have come on record… the lapses on the part of the Drug department would be beneficial to the manufacturers who are manufacturing the sub-standard drugs… these drugs are adversely affecting the human beings on large scale."

3. Critique of leniency: "I am surprised by the leniency shown by the authorities while dealing with the strict time limit provided under the Rule, 1945 thereby jeopardizing the lives of public at large. When the Act or Rules provides to do a particular thing in a particular manner and if the Authorities are sitting idle, under such circumstances, it is necessary to hold the concerned officer responsible."

4. On the Act's objectives: "Due to the conduct of the concerned officers, the objectives with which the Act was enacted is getting frustrated." This ties delays to broader public health failures, as echoed in accompanying reports: "failure to analyse drug samples within the stipulated period not only vitiates prosecutions but also jeopardises public health by allowing sub-standard drugs to remain in circulation."

These observations emphasize that while protecting public health is paramount, enforcement must respect due process to avoid miscarriages of justice.

Court's Decision

The Bombay High Court unequivocally allowed the writ petition, quashing the criminal prosecution in S.C.C. No. 637/2023 pending before the Chief Judicial Magistrate, Gadchiroli. In clear terms, Justice Nerlikar held: "Considering the above facts and circumstances of the present case, the prosecution cannot sustain and the Writ Petition is allowed in terms of prayer clause (II)." The decision rests on the undisputed violation of Rule 45, absent any timely extension or reasons, rendering the proceedings unsustainable.

Beyond quashing, the court issued detailed, binding directions to the Commissioner of Food and Drugs Administration, Maharashtra, to be implemented within three months:

• Ensure strict compliance with Rule 45 timelines for sample reports.
• Take disciplinary action against officers failing to adhere to the Act and Rules.
• Request additional laboratories from the government if workload causes delays.
• Mandate that Government Analysts seek extensions immediately with written reasons if the 60-day limit cannot be met.
• Act promptly on extension requests to foster coordination.
• Develop an efficient online system for real-time tracking of drug samples and reports, preferably web-hosted for transparency.

Compliance is to be reported to the court, with the matter listed for review on May 4, 2026. The Assistant Public Prosecutor was directed to communicate the order to the Commissioner.

The practical effects are multifaceted. For the petitioners, it halts a potentially damaging prosecution, affirming that procedural fairness is non-negotiable in regulatory crimes. More broadly, it reinforces judicial oversight of administrative lapses, potentially reducing frivolous or defective cases against manufacturers while pressuring the Drugs Department to professionalize operations. Future cases may see stricter scrutiny of timelines, with courts less tolerant of delays, possibly leading to more quashings if compliance falters. This could streamline prosecutions but risks overburdening labs without infrastructure upgrades.

For legal professionals, the ruling signals a blueprint for challenging drug-related FIRs on procedural grounds, emphasizing precedents like Swapnil . It may spur legislative or administrative reforms, such as nationwide online portals, aligning with Karnataka's model and enhancing accountability. Ultimately, by balancing manufacturer rights with public safety, the decision strengthens the Act's efficacy, ensuring sub-standard drugs face robust, timely scrutiny without compromising justice.